Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib vs placebo in advanced hepatocellular carcinoma after prior antiangiogenic therapy (A4061058)
jRCT2080221284Phase 2
- Sponsor
- Pfizer
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Axitinib + best supportive care with Placebo + best supportive care (2 arms).
02
Drugs
axitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080221284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221284.